A Phase 3 interventional study of vildagliptin + acarbose and acarbose + vildagliptin in Type 2 Diabetes and Endothelial Dysfunction, sponsored by Radboud University Medical Center. Completed at 1 site in Netherlands. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-11-05.
Sponsored by Radboud University Medical Center · Phase 3, Interventional, and Prevention
Rationale: Cardiovascular complications in type 2 diabetes are the leading cause of morbidity and mortality associated with the disease. Endothelial dysfunction is regarded as an important factor in these vascular complications.
The introduction of glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes is of special interest because of possible influences on endothelial function. Numerous reports have shown that GLP-1 improves endothelial function.
Objective: To determine whether a four week treatment with vildagliptin compared to acarbose improves endothelial dysfunction in patients with type 2 diabetes mellitus.
9,589 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,332 are open to participants now.
This study's planned enrollment of 16 is below the median of 81 across 7,713 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Radboud University Medical Center is the lead sponsor of 984 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: vildagliptin + acarbose
Drug: acarbose + vildagliptin
Drug pages: Vildagliptin · Acarbose
4 week treatment
Drug pages: Acarbose · Vildagliptin
4 week treatment
Forearm vasodilator response to intra-arterial infusion of acetylcholine (endothelium-dependent) following treatment with vildagliptin and following active control with acarbose
Time frame: 8 weeks
Effect of vildagliptin on inflammatory markers and adipokines
Time frame: 8 weeks
Effect of vildagliptin on fat cell morphology and gene expression
Time frame: 8 weeks
Effect of vildagliptin on ex vivo mononuclear cell responses to various stimuli
Time frame: 8 weeks
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vildagliptin · Acarbose
Radboud University Medical Center →